BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu JHY, Foote C, Blomster J, Toyama T, Perkovic V, Sundström J, Neal B. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. The Lancet Diabetes & Endocrinology 2016;4:411-9. [DOI: 10.1016/s2213-8587(16)00052-8] [Cited by in Crossref: 311] [Cited by in F6Publishing: 338] [Article Influence: 44.4] [Reference Citation Analysis]
Number Citing Articles
1 Moon JS, Kim NH, Na JO, Cho JH, Jeong IK, Lee SH, Mok JO, Kim NH, Chung DJ, Cho J, Lee DW, Lee SW, Won KC. Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance. Diabetes Metab J 2023;47:82-91. [PMID: 35722684 DOI: 10.4093/dmj.2021.0356] [Reference Citation Analysis]
2 Diallo A, Carlos-Bolumbu M, Renard PE, Galtier F. Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with glucagon-like peptide-1 receptor agonists (GLP-1RAs): A pooled analysis of type 2 diabetes trials. Diabetes Obes Metab 2023;25:166-76. [PMID: 36057779 DOI: 10.1111/dom.14859] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Altowayan WM. Empagliflozin induced euglycemic diabetic ketoacidosis. A case reports. Ann Med Surg (Lond) 2022;84:104879. [PMID: 36582864 DOI: 10.1016/j.amsu.2022.104879] [Reference Citation Analysis]
4 Wang D, Liu J, Zhong L, Li S, Zhou L, Zhang Q, Li M, Xiao X. The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1045235] [Reference Citation Analysis]
5 Bao W, Zhang M, Li N, Yao Z, Sun L. Efficacy and safety of finerenone in chronic kidney disease associated with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. Eur J Clin Pharmacol 2022. [PMID: 36273065 DOI: 10.1007/s00228-022-03408-w] [Reference Citation Analysis]
6 Mounsey SJ, Teo YX, Calonje JE, Lewis FM. Gliflozin (SGLT2 inhibitor) induced vulvitis. Int J Dermatol 2022. [PMID: 36250299 DOI: 10.1111/ijd.16449] [Reference Citation Analysis]
7 Xu C, He L, Zhang J, Xu L, Dong J, Liao L. The Cardiovascular Benefits and Infections Risk of SGLT2i versus Metformin in Type 2 Diabetes: A Systemic Review and Meta-Analysis. Metabolites 2022;12:979. [DOI: 10.3390/metabo12100979] [Reference Citation Analysis]
8 Shafiq A, Mahboob E, Samad MA, Ur Rehman MH, Tharwani ZH. The dual role of empagliflozin: Cardio renal protection in T2DM patients. Annals of Medicine and Surgery 2022;81:104555. [DOI: 10.1016/j.amsu.2022.104555] [Reference Citation Analysis]
9 Kinoshita M, Azuma K, Yanagawa T. A case of sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis complicated by concurrent subacute thyroiditis. Journal of Clinical and Translational Endocrinology: Case Reports 2022;25:100124. [DOI: 10.1016/j.jecr.2022.100124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Luo F, Sun L, Wang Z, Zhang Y, Li J, Chen Y, Dong J. Effect of Dapagliflozin on the Outcome of Radiofrequency Catheter Ablation in Patients with Type 2 Diabetes Mellitus and Atrial Fibrillation. Cardiovasc Drugs Ther 2022. [PMID: 35962156 DOI: 10.1007/s10557-022-07368-2] [Reference Citation Analysis]
11 Wu YJ, Wang SB, Wang LS. SGLT2 Inhibitors: New Hope for the Treatment of Acute Myocardial Infarction? Am J Cardiovasc Drugs 2022. [PMID: 35947249 DOI: 10.1007/s40256-022-00545-6] [Reference Citation Analysis]
12 Lin T, Chen Y, Huang J, Liao P, Chen M, Pan L, Jong G. Sodium-glucose co-transporter-2 inhibitors reduce the risk of new-onset stroke in patients with type 2 diabetes: A population-based cohort study. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.966708] [Reference Citation Analysis]
13 Bellanti F, Lo Buglio A, Dobrakowski M, Kasperczyk A, Kasperczyk S, Aich P, Singh SP, Serviddio G, Vendemiale G. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease. World J Gastroenterol 2022; 28(26): 3243-3257 [DOI: 10.3748/wjg.v28.i26.3243] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Gitto M, Kotinas AS, Terzi R, Oliva A, Zagoreo J, Reimers B, Stefanini GG, Mirani M, Favacchio G, Condorelli G, Panico C. Biochemical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors by Cardiovascular Risk Profile and Volume Status in a Real-World Diabetic Population. J Cardiovasc Pharmacol 2022;80:140-7. [PMID: 35436244 DOI: 10.1097/FJC.0000000000001280] [Reference Citation Analysis]
15 Yoshikawa T, Mifune Y, Inui A, Nishimoto H, Yamaura K, Mukohara S, Shinohara I, Kuroda R. Quercetin treatment protects the Achilles tendons of rats from oxidative stress induced by hyperglycemia. BMC Musculoskelet Disord 2022;23:563. [PMID: 35689230 DOI: 10.1186/s12891-022-05513-4] [Reference Citation Analysis]
16 Seo B, Su J, Song Y. Exploring heterogeneities of cardiovascular efficacy and effectiveness of SGLT2 inhibitors in patients with type 2 diabetes: an umbrella review of evidence from randomized clinical trials versus real-world observational studies. Eur J Clin Pharmacol. [DOI: 10.1007/s00228-022-03327-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Xu B, Li S, Kang B, Zhou J. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovasc Diabetol 2022;21:83. [PMID: 35614469 DOI: 10.1186/s12933-022-01512-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Lin Y, Zhang H, Zhao S, Chen L, Li J, Wang X, Tian W. The Efficacy and Safety of the Combined Therapy of Sodium-Glucose Co-Transporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitor in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Sub-Analysis. Front Cardiovasc Med 2022;9:882089. [DOI: 10.3389/fcvm.2022.882089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Mukhopadhyay P, Sanyal D, Chatterjee P, Pandit K, Ghosh S. Different SGLT 2 inhibitors: Can they prevent death? Endocr Pract 2022:S1530-891X(22)00513-4. [PMID: 35569736 DOI: 10.1016/j.eprac.2022.05.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Wei W, Liu J, Chen S, Xu X, Guo D, He Y, Huang Z, Wang B, Huang H, Li Q, Chen J, Chen H, Tan N, Liu Y. Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis. Front Endocrinol (Lausanne) 2022;13:850836. [PMID: 35330914 DOI: 10.3389/fendo.2022.850836] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Cervo A, Sebastiani G, Milic J, Krahn T, Mazzola S, Petta S, Cascio A, Guaraldi G, Mazzola G. "Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV". HIV Med 2022. [PMID: 35199429 DOI: 10.1111/hiv.13274] [Reference Citation Analysis]
22 Shi FH, Yue J, Jiang YH, Yang ML, Gu ZC, Ma J, Li H. Sodium-Glucose Co-Transporter 2 Inhibitors Use Improves the Satisfaction With Anti-diabetic Agent Treatment: A Questionnaire-based Propensity Score-matched Study. Front Pharmacol 2021;12:787704. [PMID: 35177981 DOI: 10.3389/fphar.2021.787704] [Reference Citation Analysis]
23 Kim EM, Kim SS, Chung YJ. Lowering of Blood Glucose Levels with the Peptide Mixture Deglusterol in In Vitro and In Vivo Models. J Med Food 2022;25:166-76. [PMID: 35148196 DOI: 10.1089/jmf.2021.K.0159] [Reference Citation Analysis]
24 Dahlén AD, Dashi G, Maslov I, Attwood MM, Jonsson J, Trukhan V, Schiöth HB. Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales. Front Pharmacol 2022;12:807548. [DOI: 10.3389/fphar.2021.807548] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
25 Secnik J, Xu H, Schwertner E, Hammar N, Alvarsson M, Winblad B, Eriksdotter M, Garcia-Ptacek S, Religa D. Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia. J Alzheimers Dis 2022;86:245-57. [PMID: 35034902 DOI: 10.3233/JAD-215337] [Reference Citation Analysis]
26 Serik S, National Institute of Therapy L.T. Malaya NAMS of Ukraine, Kharkiv, Ukraine, Strona V, National Institute of Therapy L.T. Malaya NAMS of Ukraine, Kharkiv, Ukraine. Modern approaches to the treatment of atrial fibrillation in patients with diabetes mellitus. Shidnoevr z vnutr simejnoi med 2022;2022:69-85. [DOI: 10.15407/internalmed2022.01.069] [Reference Citation Analysis]
27 Arioglu-inan E, Kayki-mutlu G. Diuretic Agents. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00162-6] [Reference Citation Analysis]
28 Fedyaeva V, Ryzhov A. Efficacy of dapagliflozin and empagliflozin for prevention of cardiovascular complications in patients with type 2 diabetes mellitus: a network meta-analysis. Med Tech Asses and Choice 2022. [DOI: 10.17116/medtech20224404142] [Reference Citation Analysis]
29 Xu J, Hirai T, Koya D, Kitada M. Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches. J Clin Med 2021;11:137. [PMID: 35011882 DOI: 10.3390/jcm11010137] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
30 Benedetti R, Benincasa G, Glass K, Chianese U, Vietri MT, Congi R, Altucci L, Napoli C. Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials. Pharmacol Res 2021;175:106039. [PMID: 34929299 DOI: 10.1016/j.phrs.2021.106039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
31 Du Y, Bai L, Fan B, Ding H, Ding H, Hou L, Ma H, Xing N, Wang F. Effect of SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists on diabetic foot-related extremity amputation in patients with T2DM: A meta-analysis. Prim Care Diabetes 2021:S1751-9918(21)00223-0. [PMID: 34930687 DOI: 10.1016/j.pcd.2021.12.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Mannucci E, Giaccari A, Gallo M, Targher G, Pintaudi B, Candido R, Monami M. Effects of pioglitazone on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases 2021. [DOI: 10.1016/j.numecd.2021.12.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Alabdaljabar MS, Abdullah KM, Almasood A, Ali SS, Ashmeg A. Euglycemic Diabetic Ketoacidosis in a Sedated Patient after Coronary Artery Bypass Grafting: A Case Report and Literature Review. Case Rep Med 2021;2021:2086520. [PMID: 34840578 DOI: 10.1155/2021/2086520] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
34 Shi FH, Li H, Shen L, Xu L, Ge H, Gu ZC, Lin HW, Pu J. Beneficial Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Left Ventricular Function. J Clin Endocrinol Metab 2021:dgab834. [PMID: 34791312 DOI: 10.1210/clinem/dgab834] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Ku EJ, Lee DH, Jeon HJ, Oh TK. Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study. Diabetes Res Clin Pract 2021;182:109123. [PMID: 34740742 DOI: 10.1016/j.diabres.2021.109123] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
36 Kanie T, Mizuno A, Takaoka Y, Suzuki T, Yoneoka D, Nishikawa Y, Tam WWS, Morze J, Rynkiewicz A, Xin Y, Wu O, Providencia R, Kwong JS. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev 2021;10:CD013650. [PMID: 34693515 DOI: 10.1002/14651858.CD013650.pub2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
37 Tang EHM, Wong CKH, Lau KTK, Fei Y, Cheung BMY. Cardio-renal outcomes and the direct medical cost of type 2 diabetes patients treated with sodium glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based cohort study. Diabetes Res Clin Pract 2021;180:109071. [PMID: 34592391 DOI: 10.1016/j.diabres.2021.109071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Rahhal A, Najim M, Abusweireh A, Habra M, Elgassim L, Ali MO, Habib MB, Tahtouh R, Al-Awad M, Aljundi AH, Mahfouz A, Ali MT, Dabdoob W, Alyafei S, Asaad N. A Comparative Study of Safety Outcomes of Sodium Glucose Cotransporter-2 Inhibitors and Loop Diuretics Among Diabetic Patients Using Real-world Data. Curr Probl Cardiol 2021;:100995. [PMID: 34571107 DOI: 10.1016/j.cpcardiol.2021.100995] [Reference Citation Analysis]
39 Petunina NA, Telnova ME, Kuzina IA. Effect of ipragliflozin on metabolic syndrome components and non-alcoholic fatty liver disease. Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-12-305-310] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Del Vecchio L, Beretta A, Jovane C, Peiti S, Genovesi S. A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease. Drugs 2021;81:1491-511. [PMID: 34363606 DOI: 10.1007/s40265-021-01573-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
41 Edel K, Mootz R. Optimale medikamentöse Therapie bei Typ‑2-Diabetikern mit einer koronaren Herzerkrankung – Update 2021. Z Herz- Thorax- Gefäßchir 2021;35:201-210. [DOI: 10.1007/s00398-021-00446-x] [Reference Citation Analysis]
42 Liu L, Ni YQ, Zhan JK, Liu YS. The Role of SGLT2 Inhibitors in Vascular Aging. Aging Dis 2021;12:1323-36. [PMID: 34341711 DOI: 10.14336/AD.2020.1229] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
43 Sousa LS, Nascimento FDA, Rocha J, Rocha-parise M. Cardioprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors Regardless of Type 2 Diabetes Mellitus: A Meta-analysis. International Journal of Cardiovascular Sciences 2021. [DOI: 10.36660/ijcs.20200339] [Reference Citation Analysis]
44 Tian L, Cai Y, Zheng H, Ai S, Zhou M, Luo Q, Tang J, Liu W, Wang Y. Canagliflozin for Prevention of Cardiovascular and Renal Outcomes in type2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Front Pharmacol 2021;12:691878. [PMID: 34349651 DOI: 10.3389/fphar.2021.691878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Schwarzenbach M, Bernhard FE, Czerlau C, Sidler D. Chances and risks of sodium-glucose cotransporter 2 inhibitors in solid organ transplantation: A review of literatures. World J Transplant 2021; 11(7): 254-262 [PMID: 34316450 DOI: 10.5500/wjt.v11.i7.254] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Real J, Vlacho B, Ortega E, Vallés JA, Mata-Cases M, Castelblanco E, Wittbrodt ET, Fenici P, Kosiborod M, Mauricio D, Franch-Nadal J. Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia. Cardiovasc Diabetol 2021;20:139. [PMID: 34243779 DOI: 10.1186/s12933-021-01323-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
47 Villevalde SV, Galyavich AS, Vinogradova NG, Volodina EN, Gaisin IR, Gilyarevsky SR, Grekhova LV, Guryanova YA, Guseva PS, Duplyakov DV, Ezhov AV, Zakirova NE, Zolotova YV, Isakov AV, Kanysheva SV, Kim ZF, Kuzmin VP, Markiyanova SS, Pomosov SA, Rebrov AP, Tarlovskaya EI, Tolstov SN, Fomin IV, Khasanov NR, Shutov AM. Resolution of an online meeting of the Volga Federal District experts on the EMPEROR-Reduced trial “A new era in the treatment of patients with HF. From EMPA-REG OUTCOME to EMPEROR-Reduced trial”. Russ J Cardiol 2021;26:4562. [DOI: 10.15829/1560-4071-2021-4562] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Yoneda M, Honda Y, Ogawa Y, Kessoku T, Kobayashi T, Imajo K, Ozaki A, Nogami A, Taguri M, Yamanaka T, Kirikoshi H, Iwasaki T, Kurihashi T, Saito S, Nakajima A. Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial.BMJ Open Diabetes Res Care. 2021;9. [PMID: 33593749 DOI: 10.1136/bmjdrc-2020-001990] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
49 McGovern AP, Hogg M, Shields BM, Sattar NA, Holman RR, Pearson ER, Hattersley AT, Jones AG, Dennis JM; MASTERMIND consortium. Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Res Care 2020;8:e001238. [PMID: 32448787 DOI: 10.1136/bmjdrc-2020-001238] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
50 Martínez-Vizcaíno V, Díez-Fernández A, Álvarez-Bueno C, Martínez-Alfonso J, Cavero-Redondo I. Safety and Efficacy of SGLT2 Inhibitors: A Multiple-Treatment Meta-Analysis of Clinical Decision Indicators. J Clin Med 2021;10:2713. [PMID: 34205385 DOI: 10.3390/jcm10122713] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Scoccimarro D, Cipani G, Dicembrini I, Mannucci E. Cigarette Smoking as a Predictor of Sodium-Glucose Cotransporter 2 Inhibitor-Associated Genital Infections: A Retrospective Cohort Study. Diabetes Care 2021;44:e127-8. [PMID: 33883197 DOI: 10.2337/dc21-0308] [Reference Citation Analysis]
52 . Chinese Guideline on the Primary Prevention of Cardiovascular Diseases. Cardiology Discovery 2021;1:70-104. [DOI: 10.1097/cd9.0000000000000025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
53 Lu H, Lu H, Kosinski C, Wojtusciszyn A, Zanchi A, Carron PN, Müller M, Meyer P, Martin J, Muller O, Hullin R. SGLT2 Inhibitors, What the Emergency Physician Needs to Know: A Narrative Review. J Clin Med 2021;10:2036. [PMID: 34068655 DOI: 10.3390/jcm10092036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
54 Kyriakos G, Quiles-Sanchez LV, Garmpi A, Farmaki P, Kyre K, Savvanis S, Antoniou VK, Memi E. SGLT2 Inhibitors and Cardiovascular Outcomes: Do they Differ or there is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study. Curr Cardiol Rev 2020;16:258-65. [PMID: 31362691 DOI: 10.2174/1573403X15666190730094215] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Chehrehgosha H, Sohrabi MR, Ismail-Beigi F, Malek M, Reza Babaei M, Zamani F, Ajdarkosh H, Khoonsari M, Fallah AE, Khamseh ME. Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Diabetes Ther. 2021;12:843-861. [PMID: 33586120 DOI: 10.1007/s13300-021-01011-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
56 Benham JL, Booth JE, Sigal RJ, Daskalopoulou SS, Leung AA, Rabi DM. Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes. Int J Cardiol Heart Vasc 2021;33:100725. [PMID: 33659605 DOI: 10.1016/j.ijcha.2021.100725] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
57 Fralick M, Redelmeier DA, Patorno E, Franklin JM, Razak F, Gomes T, Schneeweiss S. Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 Inhibitors: a Nationwide Cohort Study in the USA. J Gen Intern Med 2021;36:2601-7. [PMID: 33564942 DOI: 10.1007/s11606-020-06561-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
58 Huang J, Xiong S, Ding S, Cheng Q, Liu Z. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Conventional Therapy at Different Periods: A Meta-Analysis of Randomized Controlled Trials. J Diabetes Res 2020;2020:9704659. [PMID: 33532502 DOI: 10.1155/2020/9704659] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 Toyama T. Clinical Epidemiology. Diabetic Kidney Disease 2021. [DOI: 10.1007/978-981-15-9301-7_1] [Reference Citation Analysis]
60 Wagdy K. The EMPEROR-Reduced trial: SGLT2 inhibitors for heart failure get more support. Glob Cardiol Sci Pract 2020;2020:e202031. [PMID: 33598491 DOI: 10.21542/gcsp.2020.31] [Reference Citation Analysis]
61 Mantovani A, Petracca G, Csermely A, Beatrice G, Targher G. Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Metabolites 2020;11:22. [PMID: 33396949 DOI: 10.3390/metabo11010022] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 10.7] [Reference Citation Analysis]
62 Fathi A, Vickneson K, Singh JS. SGLT2-inhibitors; more than just glycosuria and diuresis. Heart Fail Rev 2021;26:623-42. [PMID: 33274396 DOI: 10.1007/s10741-020-10038-w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
63 Bauduceau B, Bordier L. La dapagliflozine (Forxiga® et Xigduo®). Médecine des Maladies Métaboliques 2020;14:744-753. [DOI: 10.1016/j.mmm.2020.10.007] [Reference Citation Analysis]
64 Wagdy K, Selwanos P. DAPA-HF trial signals the birth of 'diabetic cardiology' and more. Glob Cardiol Sci Pract 2020;2020:e202022. [PMID: 33426039 DOI: 10.21542/gcsp.2020.22] [Reference Citation Analysis]
65 Siasos G, Bletsa E, Stampouloglou PK, Paschou SA, Oikonomou E, Tsigkou V, Antonopoulos AS, Vavuranakis M, Tousoulis D. Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes. Curr Pharm Des 2020;26:5911-32. [PMID: 33167826 DOI: 10.2174/1381612826666201109110107] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
66 Rieth AJ, Hamm CW, Wanner C, Mitrovic V, Keller T. [Heart failure protection by SGLT2 inhibitors in patients with type 2 diabetes mellitus: evidence and possible mechanisms : A systematic review]. Herz 2021;46:151-8. [PMID: 33044563 DOI: 10.1007/s00059-020-04994-0] [Reference Citation Analysis]
67 Zou H, Liu L, Guo J, Wang H, Liu S, Xing Y, Deng C, Xiao Y, Zhou Z. Sodium-glucose cotransporter inhibitors as add-on therapy in addition to insulin for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials. J Diabetes Investig 2021;12:546-56. [PMID: 33245620 DOI: 10.1111/jdi.13387] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
68 Shao SC, Lin YH, Chang KC, Chan YY, Hung MJ, Kao Yang YH, Lai EC. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients? BMJ Open Diabetes Res Care 2019;7:e000742. [PMID: 32043472 DOI: 10.1136/bmjdrc-2019-000742] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
69 Scheen AJ. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2020;16:556-77. [PMID: 32855502 DOI: 10.1038/s41574-020-0392-2] [Cited by in Crossref: 90] [Cited by in F6Publishing: 95] [Article Influence: 30.0] [Reference Citation Analysis]
70 Ramos M, Cummings MH, Ustyugova A, Raza SI, de Silva SU, Lamotte M. Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK. Diabetes Ther 2020;11:2041-55. [PMID: 32700188 DOI: 10.1007/s13300-020-00883-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
71 Kanie T, Mizuno A, Yoneoka D, Tam WWS, Morze J, Rynkiewicz A, Xin Y, Wu O, Kwong JS. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database of Systematic Reviews 2020. [DOI: 10.1002/14651858.cd013650] [Reference Citation Analysis]
72 Castellana M, Procino F, Sardone R, Trimboli P, Giannelli G. Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis. Cardiovasc Diabetol 2020;19:87. [PMID: 32534590 DOI: 10.1186/s12933-020-01067-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
73 Panevin TS, Eliseev MS, Shestakova MV, Nasonov EL. [Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout]. Ter Arkh 2020;92:110-8. [PMID: 32598783 DOI: 10.26442/00403660.2020.05.000633] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
74 Srivastava SP, Goodwin JE. Cancer Biology and Prevention in Diabetes. Cells 2020;9:E1380. [PMID: 32498358 DOI: 10.3390/cells9061380] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
75 Nicolas J, Claessen B, Mehran R. Implications of Kidney Disease in the Cardiac Patient. Interv Cardiol Clin 2020;9:265-78. [PMID: 32471668 DOI: 10.1016/j.iccl.2020.03.002] [Reference Citation Analysis]
76 Pelletier R, Ng K, Alkabbani W, Labib Y, Mourad N, Gamble JM. The association of sodium-glucose cotransporter 2 inhibitors with cancer: An overview of quantitative systematic reviews. Endocrinol Diabetes Metab 2020;3:e00145. [PMID: 32704566 DOI: 10.1002/edm2.145] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
77 Giorgino F, Vora J, Fenici P, Solini A. Cardiovascular protection with sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Does it apply to all patients? Diabetes Obes Metab 2020;22:1481-95. [PMID: 32285611 DOI: 10.1111/dom.14055] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
78 Yang Y, Zhao C, Ye Y, Yu M, Qu X. Prospect of Sodium-Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes. Front Endocrinol (Lausanne) 2020;11:190. [PMID: 32351447 DOI: 10.3389/fendo.2020.00190] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
79 Koenig W, Rosner S. SGLT2-Hemmer, die neue Allzweckwaffe? CV 2020;20:36-45. [DOI: 10.1007/s15027-020-0415-x] [Reference Citation Analysis]
80 Hu M, Cai X, Yang W, Zhang S, Nie L, Ji L. Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis. J Am Heart Assoc 2020;9:e015323. [PMID: 32223390 DOI: 10.1161/JAHA.119.015323] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
81 Deng B, Henan University of Science and Technology, Luoyang, PRС, Kireev V, Melentyeva K, Kovalenko I, Pakhomov O, Institute for Problems of Cryobiology and Cryomedicine of the National Academy of Sciences of Ukraine, Kharkiv, Ukraine, SI ‘I.I. Mechnikov Institute of Microbiology and Immunology of the National Academy of Medical Sciences of Ukraine’, Kharkiv, Ukraine, Institute for Problems of Cryobiology and Cryomedicine of the National Academy of Sciences of Ukraine, Kharkiv, Ukraine, Institute for Problems of Cryobiology and Cryomedicine of the National Academy of Sciences of Ukraine, Kharkiv, Ukraine. Histology of Cryopreserved Neonatal Rat Testes After Intratesticular Allotransplantation. Probl Cryobiol Cryomed 2020;30:034-046. [DOI: 10.15407/cryo30.01.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
82 Rahadian A, Fukuda D, Salim HM, Yagi S, Kusunose K, Yamada H, Soeki T, Sata M. Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice. J Atheroscler Thromb 2020;27:1141-51. [PMID: 32101837 DOI: 10.5551/jat.52100] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
83 Fralick M, Chen SK, Patorno E, Kim SC. Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study. Ann Intern Med 2020;172:186-94. [PMID: 31931526 DOI: 10.7326/M19-2610] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 11.3] [Reference Citation Analysis]
84 Conte C, Bouillon R, Napoli N. Diabetes and bone. Principles of Bone Biology 2020. [DOI: 10.1016/b978-0-12-814841-9.00040-3] [Reference Citation Analysis]
85 Zou CY, Liu XK, Sang YQ, Wang B, Liang J. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis. Medicine (Baltimore) 2019;98:e18245. [PMID: 31804352 DOI: 10.1097/MD.0000000000018245] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 10.3] [Reference Citation Analysis]
86 Echouffo-Tcheugui JB, Xu H, Matsouaka RA, Xian Y, Schwamm LH, Smith EE, Bhatt DL, Hernandez AF, Heidenreich PA, Fonarow GC. Diabetes and long-term outcomes of ischaemic stroke: findings from Get With The Guidelines-Stroke. Eur Heart J 2018;39:2376-86. [PMID: 29438515 DOI: 10.1093/eurheartj/ehy036] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 11.0] [Reference Citation Analysis]
87 Yokoyama H. Incidence of severe urinary tract infections not increased by initiating sodium-glucose cotransporter 2 inhibitors. J Diabetes Investig 2020;11:530-1. [PMID: 31763787 DOI: 10.1111/jdi.13189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
88 Canivell S, Mata-Cases M, Vlacho B, Gratacòs M, Real J, Mauricio D, Franch-Nadal J. How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area. J Diabetes Res 2019;2019:2018374. [PMID: 31815146 DOI: 10.1155/2019/2018374] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
89 Hasan MN, Sabrin F, Rokeya B, Khan MSH, Ahmed MU, Matondo A, Billah MM, Akter S. Glucose and lipid lowering effects of Enhydra fluctuans extract in cadmium treated normal and type-2 diabetic model rats. BMC Complement Altern Med 2019;19:278. [PMID: 31640743 DOI: 10.1186/s12906-019-2667-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
90 Kashiwagi A, Shestakova MV, Ito Y, Noguchi M, Wilpshaar W, Yoshida S, Wilding JPH. Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials. Diabetes Ther 2019;10:2201-17. [PMID: 31606880 DOI: 10.1007/s13300-019-00699-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
91 Rodler S, Weig T, Finkenzeller C, Stief C, Staehler M. Fournier´s Gangrene Under Sodium-Glucose Cotransporter 2 Inhibitor Therapy as a Life-Threatening Adverse Event: A Case Report and Review of the Literature. Cureus 2019;11:e5778. [PMID: 31723537 DOI: 10.7759/cureus.5778] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
92 Shi FH, Li H, Shen L, Zhang Z, Jiang YH, Hu YM, Liu XY, Gu ZC, Ma J, Lin HW. Appraisal of Non-Cardiovascular Safety for Sodium-Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials. Front Pharmacol 2019;10:1066. [PMID: 31616297 DOI: 10.3389/fphar.2019.01066] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
93 Scheen AJ. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. Circ Res 2018;122:1439-59. [PMID: 29748368 DOI: 10.1161/CIRCRESAHA.117.311588] [Cited by in Crossref: 171] [Cited by in F6Publishing: 181] [Article Influence: 42.8] [Reference Citation Analysis]
94 Lăcătușu CM, Grigorescu ED, Stătescu C, Sascău RA, Onofriescu A, Mihai BM. Association of Antihyperglycemic Therapy with Risk of Atrial Fibrillation and Stroke in Diabetic Patients. Medicina (Kaunas) 2019;55:E592. [PMID: 31540142 DOI: 10.3390/medicina55090592] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
95 Schwarz PEH, Timpel P, Harst L, Greaves CJ, Ali MK, Lambert J, Weber MB, Almedawar MM, Morawietz H. Blood Sugar Regulation for Cardiovascular Health Promotion and Disease Prevention: JACC Health Promotion Series. J Am Coll Cardiol 2018;72:1829-44. [PMID: 30286928 DOI: 10.1016/j.jacc.2018.07.081] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
96 Diaz-Ramos A, Eilbert W, Marquez D. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature. Int J Emerg Med 2019;12:27. [PMID: 31488052 DOI: 10.1186/s12245-019-0240-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 10.0] [Reference Citation Analysis]
97 Dorsey-Treviño EG, González-González JG, Alvarez-Villalobos N, González-Nava V, Contreras-Garza BM, Díaz González-Colmenero A, Rodríguez-Tamez G, Barrera-Flores FJ, Farrell AM, Montori VM, Rodriguez-Gutierrez R. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis. J Endocrinol Invest 2020;43:289-304. [PMID: 31489568 DOI: 10.1007/s40618-019-01103-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
98 Fei Y, Tsoi MF, Cheung BMY. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. Cardiovasc Diabetol 2019;18:112. [PMID: 31462224 DOI: 10.1186/s12933-019-0916-z] [Cited by in Crossref: 84] [Cited by in F6Publishing: 85] [Article Influence: 21.0] [Reference Citation Analysis]
99 Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N. SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. Int J Environ Res Public Health 2019;16:E2965. [PMID: 31426529 DOI: 10.3390/ijerph16162965] [Cited by in Crossref: 80] [Cited by in F6Publishing: 85] [Article Influence: 20.0] [Reference Citation Analysis]
100 Lyu Y, Kim J, Kim S. Pharmacotherapy of Diabetes Focused on Stroke. J Korean Neurol Assoc 2019;37:235-250. [DOI: 10.17340/jkna.2019.3.1] [Reference Citation Analysis]
101 Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study. Ann Intern Med 2019;171:248-56. [PMID: 31357213 DOI: 10.7326/M18-3136] [Cited by in Crossref: 69] [Cited by in F6Publishing: 75] [Article Influence: 17.3] [Reference Citation Analysis]
102 Garofalo C, Borrelli S, Liberti ME, Andreucci M, Conte G, Minutolo R, Provenzano M, De Nicola L. SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects. Medicina (Kaunas) 2019;55:E268. [PMID: 31212638 DOI: 10.3390/medicina55060268] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
103 Sakai T, Miura S. Effects of Sodium-Glucose Cotransporter 2 Inhibitor on Vascular Endothelial and Diastolic Function in Heart Failure With Preserved Ejection Fraction - Novel Prospective Cohort Study. Circ Rep 2019;1:286-95. [PMID: 33693152 DOI: 10.1253/circrep.CR-19-0018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
104 Carbone S, Dixon DL. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2019;18:64. [PMID: 31138195 DOI: 10.1186/s12933-019-0869-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
105 Rabizadeh S, Nakhjavani M, Esteghamati A. Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review. Int J Endocrinol Metab 2019;17:e84353. [PMID: 31372172 DOI: 10.5812/ijem.84353] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
106 Schork A, Saynisch J, Vosseler A, Jaghutriz BA, Heyne N, Peter A, Häring HU, Stefan N, Fritsche A, Artunc F. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy. Cardiovasc Diabetol 2019;18:46. [PMID: 30953516 DOI: 10.1186/s12933-019-0852-y] [Cited by in Crossref: 103] [Cited by in F6Publishing: 105] [Article Influence: 25.8] [Reference Citation Analysis]
107 Hinnen D, Kruger DF. Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials. Diabetes Metab Syndr Obes 2019;12:447-55. [PMID: 31040709 DOI: 10.2147/DMSO.S188705] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
108 Alam F, Islam MA, Mohamed M, Ahmad I, Kamal MA, Donnelly R, Idris I, Gan SH. Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Sci Rep 2019;9:5389. [PMID: 30926892 DOI: 10.1038/s41598-019-41854-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 10.5] [Reference Citation Analysis]
109 Nilsson LM, Zhang L, Bondar A, Svensson D, Wernerson A, Brismar H, Scott L, Aperia A. Prompt apoptotic response to high glucose in SGLT-expressing renal cells. Am J Physiol Renal Physiol 2019;316:F1078-89. [PMID: 30864838 DOI: 10.1152/ajprenal.00615.2018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
110 Landgraf R, Kellerer M, Aberle J, Fach E, Gallwitz B, Hamann A, Joost H, Klein H, Müller-wieland D, Nauck MA, Reuter H, Schreiber S, Siegel E. Therapie des Typ-2-Diabetes. Diabetologe 2019;15:146-67. [DOI: 10.1007/s11428-019-0459-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
111 Dey AK, Groenendyk J, Mehta NN, Gourgari E. The effect of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes. Clin Cardiol 2019;42:406-12. [PMID: 30635924 DOI: 10.1002/clc.23152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
112 Bauduceau B, Monnier L. Impact des nouvelles classes d’antidiabétiques sur le risque cardiovasculaire dans le diabète de type 2. Médecine des Maladies Métaboliques 2019;13:42-49. [DOI: 10.1016/s1957-2557(19)30023-9] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
113 Singh AK, Unnikrishnan AG, Zargar AH, Kumar A, Das AK, Saboo B, Sinha B, Gangopadhyay KK, Talwalkar PG, Ghosal S, Kalra S, Joshi S, Sharma SK, Sriram U, Mohan V. Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians. Diabetes Ther 2019;10:393-428. [PMID: 30706366 DOI: 10.1007/s13300-019-0562-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
114 Fralick M, Kim SC, Schneeweiss S, Kim D, Redelmeier DA, Patorno E. Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study. Ann Intern Med. 2019;. [PMID: 30597484 DOI: 10.7326/m18-0567] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 15.8] [Reference Citation Analysis]
115 Ko S. Oral Hypoglycemic Agents for Patients with Type 2 Diabetes Mellitus. J Korean Diabetes 2019;20:142. [DOI: 10.4093/jkd.2019.20.3.142] [Reference Citation Analysis]
116 Gupte M, Umbarkar P, Lal H. Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line : Editorial to: "Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes" by N. Hammoudi et al. Cardiovasc Drugs Ther 2017;31:229-32. [PMID: 28733758 DOI: 10.1007/s10557-017-6741-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
117 Stapff MP. Using real world data to assess cardiovascular outcomes of two antidiabetic treatment classes. World J Diabetes 2018; 9(12): 252-257 [PMID: 30588287 DOI: 10.4239/wjd.v9.i12.252] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
118 Donnan JR, Grandy CA, Chibrikov E, PharmD CM, Aubrey-Bassler K, Johnston K, Swab M, Hache J, Curnew D, Nguyen H, Gamble JM. Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials. CMAJ Open 2018;6:E594-602. [PMID: 30530719 DOI: 10.9778/cmajo.20180111] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
119 Oyebode OA, Erukainure OL, Koorbanally NA, Islam MS. Acalypha Wilkesiana 'Java White': Identification of Some Bioactive Compounds by Gc-Ms and Their Effects on Key Enzymes Linked to Type 2 Diabete. Acta Pharm 2018;68:425-39. [PMID: 31259705 DOI: 10.2478/acph-2018-0037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
120 Ueda P, Svanström H, Melbye M, Eliasson B, Svensson AM, Franzén S, Gudbjörnsdottir S, Hveem K, Jonasson C, Pasternak B. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 2018;363:k4365. [PMID: 30429124 DOI: 10.1136/bmj.k4365] [Cited by in Crossref: 186] [Cited by in F6Publishing: 191] [Article Influence: 37.2] [Reference Citation Analysis]
121 Adimadhyam S, Schumock GT, Calip GS, Smith Marsh DE, Layden BT, Lee TA. Increased risk of mycotic infections associated with sodium-glucose co-transporter 2 inhibitors: a prescription sequence symmetry analysis. Br J Clin Pharmacol 2019;85:160-8. [PMID: 30294925 DOI: 10.1111/bcp.13782] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
122 Zubiaga L, Vilallonga R, Ruiz-tovar J, Torres A, Pattou F. Importance of the Gastrointestinal Tract in Type 2 Diabetes. Metabolic Surgery Is More Than Just Incretin Effect. Cirugía Española (English Edition) 2018;96:537-45. [DOI: 10.1016/j.cireng.2018.10.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
123 Zubiaga L, Vilallonga R, Ruiz-Tovar J, Torres A, Pattou F. Importance of the gastrointestinal tract in type 2 diabetes. Metabolic surgery is more than just incretin effect. Cir Esp (Engl Ed) 2018;96:537-45. [PMID: 30337047 DOI: 10.1016/j.ciresp.2018.09.004] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
124 Dave CV, Schneeweiss S, Patorno E. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab 2019;21:434-8. [PMID: 30207042 DOI: 10.1111/dom.13531] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 10.0] [Reference Citation Analysis]
125 Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database Syst Rev 2018;9:CD011798. [PMID: 30246878 DOI: 10.1002/14651858.CD011798.pub2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
126 Qian D, Zhang T, Zheng P, Liang Z, Wang S, Xie J, Zhao L, Zhang Y, Situ B. Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis. Diabetes Ther 2018;9:1945-58. [PMID: 30121726 DOI: 10.1007/s13300-018-0482-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
127 Ito D, Inoue K, Sumita T, Hamaguchi K, Kaneko K, Yanagisawa M, Inukai K, Inoue I, Noda M, Shimada A. Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: 104-Week Follow-up of an Open-Label Study. J Clin Med Res 2018;10:679-87. [PMID: 30116437 DOI: 10.14740/jocmr3491w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
128 Budoff MJ, Wilding JPH. Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. Int J Clin Pract 2017;71. [PMID: 28508457 DOI: 10.1111/ijcp.12948] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
129 Wu B, Zheng H, Gu J, Guo Y, Liu Y, Wang Y, Chen F, Yang A, Wang J, Wang H, Liu Y, Wang D. Effects of sodium-glucose cotransporter 2 inhibitors in addition to insulin therapy on cardiovascular risk factors in type 2 diabetes patients: A meta-analysis of randomized controlled trials. J Diabetes Investig 2019;10:446-57. [PMID: 29923322 DOI: 10.1111/jdi.12876] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
130 Zhuang XD, He X, Yang DY, Guo Y, He JG, Xiao HP, Liao XX. Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials. Cardiovasc Diabetol 2018;17:79. [PMID: 29871636 DOI: 10.1186/s12933-018-0722-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
131 Galderisi A, Sherr J, VanName M, Carria L, Zgorski M, Tichy E, Weyman K, Cengiz E, Weinzimer S, Tamborlane W. Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes. J Clin Endocrinol Metab 2018;103:1088-94. [PMID: 29211871 DOI: 10.1210/jc.2017-02265] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
132 Dao-Tran TH, Anderson D, Chang A, Seib C, Hurst C. Factors associated with self-management among Vietnamese adults with type 2 diabetes. Nurs Open 2018;5:507-16. [PMID: 30338096 DOI: 10.1002/nop2.158] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
133 Puckrin R, Saltiel MP, Reynier P, Azoulay L, Yu OHY, Filion KB. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 2018;55:503-14. [PMID: 29484489 DOI: 10.1007/s00592-018-1116-0] [Cited by in Crossref: 101] [Cited by in F6Publishing: 80] [Article Influence: 20.2] [Reference Citation Analysis]
134 Gallwitz B. The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors - Real-World Data. Eur Endocrinol 2018;14:17-23. [PMID: 29922347 DOI: 10.17925/EE.2018.14.1.17] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
135 Saad M. Sodium-glucose cotransporter-2 inhibitors and cardiovascular outcomes: insights from the CVD-REAL study. Ann Transl Med 2018;6:55. [PMID: 29610747 DOI: 10.21037/atm.2017.11.08] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
136 Nordestgaard BG, Cosentino F, Landmesser U, Laufs U. The year in cardiology 2017: prevention. Cardiologia Croatica 2018;13:79-98. [DOI: 10.15836/ccar2018.79] [Reference Citation Analysis]
137 Fuentes B. Antidiabetic drugs for stroke prevention in patients with type-2 diabetes. The neurologist's point of view. Medicina Clínica (English Edition) 2018;150:275-81. [DOI: 10.1016/j.medcle.2018.01.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
138 de Vos LC, Hettige TS, Cooper ME. New Glucose-Lowering Agents for Diabetic Kidney Disease. Adv Chronic Kidney Dis 2018;25:149-57. [PMID: 29580579 DOI: 10.1053/j.ackd.2018.01.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
139 Fralick M, Avorn J, Franklin JM, Abdurrob A, Kesselheim AS. Application and impact of run-in studies. J Gen Intern Med 2018;33:759-63. [PMID: 29450684 DOI: 10.1007/s11606-018-4344-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
140 Avogaro A, De Kreutzenberg SV, Fadini GP. The impact of glucose-lowering medications on cardiovascular disease. Cardiovasc Endocrinol Metab 2018;7:13-7. [PMID: 31646273 DOI: 10.1097/XCE.0000000000000139] [Reference Citation Analysis]
141 Polidori D, Iijima H, Goda M, Maruyama N, Inagaki N, Crawford PA. Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin. Diabetes Obes Metab 2018;20:1321-6. [PMID: 29341404 DOI: 10.1111/dom.13224] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
142 Scheen A. Place des inhibiteurs des SGLT2 dans le traitement du patient diabétique de type 2. Médecine des Maladies Métaboliques 2018;12:22-30. [DOI: 10.1016/s1957-2557(18)30005-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
143 Zhang XL, Zhu QQ, Chen YH, Li XL, Chen F, Huang JA, Xu B. Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis. J Am Heart Assoc 2018;7:e007165. [PMID: 29353233 DOI: 10.1161/JAHA.117.007165] [Cited by in Crossref: 71] [Cited by in F6Publishing: 77] [Article Influence: 14.2] [Reference Citation Analysis]
144 Bianchi C, Daniele G, Dardano A, Del Prato S. Treatment with Oral Drugs. Endocrinology 2018. [DOI: 10.1007/978-3-319-45015-5_19] [Reference Citation Analysis]
145 Bianchi C, Daniele G, Dardano A, Del Prato S. Treatment with Oral Drugs. Endocrinology 2018. [DOI: 10.1007/978-3-319-27317-4_19-1] [Reference Citation Analysis]
146 José Rodríguez J, Department of cardiology, cardiovascular institute, hospital clinic, Biomedical Investigation Institute, IDIBAPS, Barcelona, Spain, Ortega-paz L, Brugaletta S, Sabaté M, † These two authors contributed equally.. Impact of SGLT2i on cardiovascular outcomes and heart failure in patients with type 2 diabetes. AIMS Medical Science 2018;5:67-79. [DOI: 10.3934/medsci.2018.1.67] [Reference Citation Analysis]
147 Gupta V, Canovatchel W, Lokesh BN, Santani R, Garodia N. Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal. Indian J Endocrinol Metab 2017;21:909-18. [PMID: 29285458 DOI: 10.4103/ijem.IJEM_85_17] [Reference Citation Analysis]
148 Verbrugge FH. Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure. Curr Heart Fail Rep 2017;14:275-83. [PMID: 28647919 DOI: 10.1007/s11897-017-0340-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
149 Aronow WS, Shamliyan TA. Comparative effectiveness and safety of empagliflozin on cardiovascular mortality and morbidity in adults with type 2 diabetes. Ann Transl Med 2017;5:455. [PMID: 29285488 DOI: 10.21037/atm.2017.08.43] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
150 Egger A, Kraenzlin ME, Meier C. Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health. Curr Osteoporos Rep 2016;14:345-50. [PMID: 27709509 DOI: 10.1007/s11914-016-0337-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
151 Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR;  CANVAS Program Collaborative Group. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137:323-334. [PMID: 29133604 DOI: 10.1161/circulationaha.117.032038] [Cited by in Crossref: 306] [Cited by in F6Publishing: 324] [Article Influence: 51.0] [Reference Citation Analysis]
152 Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World). Circulation 2018;137:1450-9. [PMID: 29133607 DOI: 10.1161/CIRCULATIONAHA.117.031227] [Cited by in Crossref: 154] [Cited by in F6Publishing: 163] [Article Influence: 25.7] [Reference Citation Analysis]
153 Pleros C, Stamataki E, Papadaki A, Damianakis N, Poulidaki R, Gakiopoulou C, Tzanakis I. Dapagliflozin as a cause of acute tubular necrosis with heavy consequences: a case report. CEN Case Rep 2018;7:17-20. [PMID: 29127652 DOI: 10.1007/s13730-017-0283-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
154 Goldberg N, Fralick M. Sodium-glucose cotransporter 2 inhibitors for treating diabetes mellitus. CMAJ 2017;189:E724. [PMID: 28536128 DOI: 10.1503/cmaj.161455] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
155 Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. Circulation 2017;136:1643-58. [PMID: 29061576 DOI: 10.1161/CIRCULATIONAHA.117.030012] [Cited by in Crossref: 260] [Cited by in F6Publishing: 279] [Article Influence: 43.3] [Reference Citation Analysis]
156 Dagogo-Jack S, Liu J, Eldor R, Amorin G, Johnson J, Hille D, Liao Y, Huyck S, Golm G, Terra SG, Mancuso JP, Engel SS, Lauring B. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab 2018;20:530-40. [PMID: 28921862 DOI: 10.1111/dom.13116] [Cited by in Crossref: 96] [Cited by in F6Publishing: 103] [Article Influence: 16.0] [Reference Citation Analysis]
157 Schnell O, Rydén L, Standl E, Ceriello A; D&CVD EASD Study Group. Updates on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol 2017;16:128. [PMID: 29020969 DOI: 10.1186/s12933-017-0610-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 6.7] [Reference Citation Analysis]
158 Fritschka E. Gliflozin schützt Herz und Hirn, aber nicht Zehen. Info Diabetol 2017;11:17-17. [DOI: 10.1007/s15034-017-1163-6] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
159 Mackie A, Honda T. Preventative Cardiology. Physician Assistant Clinics 2017;2:743-758. [DOI: 10.1016/j.cpha.2017.06.010] [Reference Citation Analysis]
160 Pecoits-Filho R, Perkovic V. Are SGLT2 Inhibitors Ready for Prime Time for CKD? Clin J Am Soc Nephrol 2018;13:318-20. [PMID: 28893920 DOI: 10.2215/CJN.07680717] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
161 Bauduceau B, Bordier L. Diabète de type 2 : les médicaments hypoglycémiants et leurs risques cardiovasculaires. Bulletin de l'Académie Nationale de Médecine 2017;201:1209-1225. [DOI: 10.1016/s0001-4079(19)30390-5] [Reference Citation Analysis]
162 Ritzel RA. Orale Triple-Therapie – sinnvolle Strategie oder nur Verzögerungstaktik? Diabetologe 2017;13:416-420. [DOI: 10.1007/s11428-017-0253-3] [Reference Citation Analysis]
163 Abdul-Ghani M, DeFronzo RA. Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. Diabetes Care 2017;40:1121-7. [PMID: 28733377 DOI: 10.2337/dc16-2368] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
164 Yu H, Woo VC. Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin. Diabetes Metab Syndr Obes 2017;10:317-32. [PMID: 28769579 DOI: 10.2147/DMSO.S117982] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
165 Nomoto H, Miyoshi H, Sugawara H, Ono K, Yanagiya S, Oita M, Nakamura A, Atsumi T. A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin. Diabetol Metab Syndr 2017;9:54. [PMID: 28725273 DOI: 10.1186/s13098-017-0255-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
166 Tampaki EC, Tampakis A, Gürke L. Letter by Tampaki et al Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk". Stroke 2017;48:e255. [PMID: 28701575 DOI: 10.1161/STROKEAHA.117.017989] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
167 Zinman B, Inzucchi SE, Diener HC. Response by Zinman et al to Letter Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk". Stroke 2017;48:e256-7. [PMID: 28701577 DOI: 10.1161/STROKEAHA.117.018125] [Reference Citation Analysis]
168 Puchalska P, Crawford PA. Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics. Cell Metab. 2017;25:262-284. [PMID: 28178565 DOI: 10.1016/j.cmet.2016.12.022] [Cited by in Crossref: 630] [Cited by in F6Publishing: 650] [Article Influence: 105.0] [Reference Citation Analysis]
169 Abdul-Ghani M, DeFronzo RA, Del Prato S, Chilton R, Singh R, Ryder REJ. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes Care 2017;40:813-20. [PMID: 28637886 DOI: 10.2337/dc16-2736] [Cited by in Crossref: 84] [Cited by in F6Publishing: 90] [Article Influence: 14.0] [Reference Citation Analysis]
170 Liu J, Li L, Li S, Jia P, Deng K, Chen W, Sun X. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep 2017;7:2824. [PMID: 28588220 DOI: 10.1038/s41598-017-02733-w] [Cited by in Crossref: 105] [Cited by in F6Publishing: 119] [Article Influence: 17.5] [Reference Citation Analysis]
171 Lundkvist P, Pereira MJ, Katsogiannos P, Sjöström CD, Johnsson E, Eriksson JW. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year. Diabetes Obes Metab 2017;19:1276-88. [PMID: 28345814 DOI: 10.1111/dom.12954] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
172 Lee G, Oh SW, Hwang SS, Yoon JW, Kang S, Joh HK, Kwon H, Kim J, Park D. Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis. PLoS One 2017;12:e0177646. [PMID: 28542373 DOI: 10.1371/journal.pone.0177646] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
173 Yanai H, Hakoshima M, Adachi H, Kawaguchi A, Waragai Y, Harigae T, Masui Y, Kakuta K, Hamasaki H, Katsuyama H, Kaga T, Sako A. Effects of Six Kinds of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters, and Summarized Effect and Its Correlations With Baseline Data. J Clin Med Res 2017;9:605-12. [PMID: 28611861 DOI: 10.14740/jocmr3046w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
174 MacIsaac RJ, Jerums G, Ekinci EI. Effects of glycaemic management on diabetic kidney disease. World J Diabetes 2017; 8(5): 172-186 [PMID: 28572879 DOI: 10.4239/wjd.v8.i5.172] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 47] [Article Influence: 7.8] [Reference Citation Analysis]
175 Tsujita M, Hossain MA, Lu R, Tsuboi T, Okumura-Noji K, Yokoyama S. Exposure to High Glucose Concentration Decreases Cell Surface ABCA1 and HDL Biogenesis in Hepatocytes. J Atheroscler Thromb 2017;24:1132-49. [PMID: 28428480 DOI: 10.5551/jat.39156] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
176 Tanaka A, Shimabukuro M, Okada Y, Taguchi I, Yamaoka-Tojo M, Tomiyama H, Teragawa H, Sugiyama S, Yoshida H, Sato Y, Kawaguchi A, Ikehara Y, Machii N, Maruhashi T, Shima KR, Takamura T, Matsuzawa Y, Kimura K, Sakuma M, Oyama JI, Inoue T, Higashi Y, Ueda S, Node K; EMBLEM Trial Investigators. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial. Cardiovasc Diabetol 2017;16:48. [PMID: 28403850 DOI: 10.1186/s12933-017-0532-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
177 Satirapoj B. Sodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects. Kidney Dis (Basel) 2017;3:24-32. [PMID: 28785561 DOI: 10.1159/000471765] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
178 Neal B, Perkovic V, Mahaffey KW, Fulcher G, Erondu N, Desai M, Shaw W, Law G, Walton MK, Rosenthal N, de Zeeuw D, Matthews DR; CANVAS Program collaborative group. Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab 2017;19:926-35. [PMID: 28244644 DOI: 10.1111/dom.12924] [Cited by in Crossref: 78] [Cited by in F6Publishing: 81] [Article Influence: 13.0] [Reference Citation Analysis]
179 Nyström T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW. Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. Diabetes Obes Metab 2017;19:831-41. [PMID: 28116795 DOI: 10.1111/dom.12889] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 10.2] [Reference Citation Analysis]
180 van Bommel EJ, Muskiet MH, Tonneijck L, Kramer MH, Nieuwdorp M, van Raalte DH. SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome. Clin J Am Soc Nephrol 2017;12:700-10. [PMID: 28254770 DOI: 10.2215/CJN.06080616] [Cited by in Crossref: 127] [Cited by in F6Publishing: 131] [Article Influence: 21.2] [Reference Citation Analysis]
181 Mazzotti A, Caletti MT, Marchignoli F, Forlani G, Marchesini G. Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease? Dig Liver Dis 2017;49:235-40. [PMID: 28089623 DOI: 10.1016/j.dld.2016.12.028] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
182 Pfeifer M, Townsend RR, Davies MJ, Vijapurkar U, Ren J. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol 2017;16:29. [PMID: 28241822 DOI: 10.1186/s12933-017-0511-0] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 10.7] [Reference Citation Analysis]
183 Minato S, Takenouchi A, Uchida J, Tsuboi A, Kurata M, Fukuo K, Kazumi T. Association of Whole Blood Viscosity With Metabolic Syndrome in Type 2 Diabetic Patients: Independent Association With Post-Breakfast Triglyceridemia. J Clin Med Res 2017;9:332-8. [PMID: 28270893 DOI: 10.14740/jocmr2885w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
184 Messana JA, Schwartz SS, Townsend RR. An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes. Vasc Health Risk Manag 2017;13:43-54. [PMID: 28255241 DOI: 10.2147/VHRM.S105721] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
185 Xu J, Rajaratnam R. Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes. Cardiovasc Diabetol. 2017;16:18. [PMID: 28148253 DOI: 10.1186/s12933-017-0499-5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 5.7] [Reference Citation Analysis]
186 Neal B, Perkovic V, Matthews DR, Mahaffey KW, Fulcher G, Meininger G, Erondu N, Desai M, Shaw W, Vercruysse F, Yee J, Deng H, de Zeeuw D; CANVAS-R Trial Collaborative Group. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial. Diabetes Obes Metab 2017;19:387-93. [PMID: 28120497 DOI: 10.1111/dom.12829] [Cited by in Crossref: 104] [Cited by in F6Publishing: 110] [Article Influence: 17.3] [Reference Citation Analysis]
187 Monami M, Dicembrini I, Mannucci E. Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. Acta Diabetol 2017;54:19-36. [PMID: 27488726 DOI: 10.1007/s00592-016-0892-7] [Cited by in Crossref: 58] [Cited by in F6Publishing: 69] [Article Influence: 9.7] [Reference Citation Analysis]
188 Chen AX, Thynne T. Sodium-glucose co-transporter 2 inhibitors: a review of their use in older people with type 2 diabetes mellitus. J Pharm Pract Res 2016;46:377-83. [DOI: 10.1002/jppr.1296] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
189 Dai Z, Nishihata Y, Kawamatsu N, Komatsu I, Mizuno A, Shimizu M, Toya N, Ishimatsu S, Komiyama N. Cardiac arrest from acute myocardial infarction complicated with sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis. J Cardiol Cases 2017;15:56-60. [PMID: 30546697 DOI: 10.1016/j.jccase.2016.10.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
190 Andrianesis V, Glykofridi S, Doupis J. The renal effects of SGLT2 inhibitors and a mini-review of the literature. Ther Adv Endocrinol Metab 2016;7:212-28. [PMID: 28203358 DOI: 10.1177/2042018816676239] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
191 Storgaard H, Gluud LL, Bennett C, Grøndahl MF, Christensen MB, Knop FK, Vilsbøll T. Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0166125. [PMID: 27835680 DOI: 10.1371/journal.pone.0166125] [Cited by in Crossref: 130] [Cited by in F6Publishing: 140] [Article Influence: 18.6] [Reference Citation Analysis]
192 Salim HM, Fukuda D, Yagi S, Soeki T, Shimabukuro M, Sata M. Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse. Front Cardiovasc Med 2016;3:43. [PMID: 27833913 DOI: 10.3389/fcvm.2016.00043] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 10.0] [Reference Citation Analysis]
193 Sano M, Takei M, Shiraishi Y, Suzuki Y. Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys. J Clin Med Res 2016;8:844-7. [PMID: 27829948 DOI: 10.14740/jocmr2760w] [Cited by in Crossref: 140] [Cited by in F6Publishing: 157] [Article Influence: 20.0] [Reference Citation Analysis]
194 Qiu R, Balis D, Capuano G, Xie J, Meininger G. Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes. Diabetes Ther 2016;7:659-78. [PMID: 27734320 DOI: 10.1007/s13300-016-0201-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
195 MacIsaac RJ, Jerums G, Ekinci EI. Cardio-renal protection with empagliflozin. Ann Transl Med 2016;4:409. [PMID: 27867961 DOI: 10.21037/atm.2016.10.36] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
196 Tanaka A, Murohara T, Taguchi I, Eguchi K, Suzuki M, Kitakaze M, Sato Y, Ishizu T, Higashi Y, Yamada H, Nanasato M, Shimabukuro M, Teragawa H, Ueda S, Kodera S, Matsuhisa M, Kadokami T, Kario K, Nishio Y, Inoue T, Maemura K, Oyama J, Ohishi M, Sata M, Tomiyama H, Node K; PROTECT Study Investigators. Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study. Cardiovasc Diabetol 2016;15:133. [PMID: 27619983 DOI: 10.1186/s12933-016-0449-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
197 Salsali A, Kim G, Woerle HJ, Broedl UC, Hantel S. Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials. Diabetes Obes Metab 2016;18:1034-40. [PMID: 27376831 DOI: 10.1111/dom.12734] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
198 Patel CA, Bailey RA, Vijapurkar U, Meininger G, Blonde L. A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures. BMC Health Serv Res 2016;16:356. [PMID: 27495291 DOI: 10.1186/s12913-016-1607-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
199 Pham D, Albuquerque Rocha N, McGuire DK, Neeland IJ. Impact of empagliflozin in patients with diabetes and heart failure. Trends Cardiovasc Med 2017;27:144-51. [PMID: 27612553 DOI: 10.1016/j.tcm.2016.07.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
200 Acevedo A, Chakera A. Gliflozin monotherapy for type 2 diabetes: a review of NICE Technology Appraisal 390. Pract Diab 2016;33:192-193. [DOI: 10.1002/pdi.2035] [Reference Citation Analysis]
201 Siegmund T. Kardiale Effekte aktueller Antidiabetika. CV 2016;16:38-42. [DOI: 10.1007/s15027-016-0915-x] [Reference Citation Analysis]
202 Wilding J. SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes? Lancet Diabetes Endocrinol 2016;4:379-81. [PMID: 27009624 DOI: 10.1016/S2213-8587(16)00084-X] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]